本页面由Tiger Trade Technology Pte. Ltd.提供服务

CRISPR Therapeutics AG

57.99
+2.274.07%
盘后58.010.0200+0.03%19:59 EDT
成交量:180.15万
成交额:1.05亿
市值:55.66亿
市盈率:-8.96
高:59.16
开:57.35
低:57.05
收:55.72
52周最高:78.48
52周最低:33.03
股本:9,598.53万
流通股本:9,053.30万
量比:1.06
换手率:1.99%
股息:- -
股息率:- -
每股收益(TTM):-6.4700
每股收益(LYR):-6.4700
净资产收益率:-30.18%
总资产收益率:-15.76%
市净率:2.90
市盈率(LYR):-8.96

数据加载中...

2019/06/26

重要事件披露

Current report, item 8.01
2019/06/19

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Initial statement of beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Initial statement of beneficial ownership of securities
2019/06/13

重要事件披露

Current report, items 5.02, 5.03, 5.07, and 9.01
2019/06/12

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/07

超过5%披露

[Amend] General statement of acquisition of beneficial ownership
2019/06/06

重要事件披露

Current report, items 1.01, 8.01, and 9.01
2019/06/04

持股变动声明

Statement of changes in beneficial ownership of securities
2019/04/29

SEC问询函

[Cover]Correspondence
2019/04/23

SEC问询函

[Cover]Correspondence
2018/12/28

超过5%披露

[Amend] General statement of acquisition of beneficial ownership
2018/12/26

超过5%披露

[Amend] General statement of acquisition of beneficial ownership
2018/02/13

超过5%披露